Showing results (11-20 of 279) with videos related to
Sort By:
Pageof 28
Urologic Oncology|July 3, 2008
New drug development in metastatic prostate cancerAndrew J Armstrong, Daniel J GeorgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2011
Better late than early: FDG-PET imaging in metastatic renal cell carcinomaMichael R Harrison, Daniel J GeorgeCurrent Opinion in Urology|March 21, 2013
Novel chemotherapies in development for management of castration-resistant prostate cancerAlok K Tewari, Daniel J GeorgeTherapeutic Advances in Urology|December 9, 2016
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidenceRachel Hu, Daniel J George, Tian ZhangThe Oncologist|November 30, 2020
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)Chester Kao, Daniel J George, Tian ZhangCurrent Opinion in Urology|April 3, 2008
Clinical endpoints for drug development in prostate cancerVeshana Ramiah, Daniel J George, Andrew J ArmstrongCancers|February 11, 2023
Clear Cell Renal Cell Carcinoma: From Biology to TreatmentAdam M Kase, Daniel J George, Sundhar RamalingamReviews in Urology|March 28, 2007
Current standard and investigational approaches to the management of hormone-refractory prostate cancerPrateek Mendiratta, Andrew J Armstrong, Daniel J GeorgeCurrent Oncology Reports|July 24, 2020
Racial Disparity in Response to Prostate Cancer Systemic TherapiesRhonda L Bitting, Michael Goodman, Daniel J GeorgeJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2012
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycinAndrew J Armstrong, Daniel J George, Susan HalabiPageof 28